Table 1 Demographic and baseline characteristics

From: Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial

 

Total (n = 70)

HR+ /HER2− (n = 50)

TNBC (n = 20)

Age (years, mean ± SD)

51.3 ± 8.29

51.0 ± 8.55

52.1 ± 7.76

Weight (kg, mean ± SD)

54.98 ± 7.084

54.50 ± 6.507

56.18 ± 8.422

BMI (kg/m2, mean ± SD)

22.10 ± 2.588

22.00 ± 2.501

22.32 ± 2.850

PS status [n (%)]

   

 0–1

43 (61.4)

30 (60.0)

13 (65.0)

 2

27 (38.6)

20 (40.0)

7 (35.0)

Menopause [n (%)]

45 (64.3)

33 (66.0)

12 (60.0)

BC duration (month)a

   

 n

69

50

19

 Mean ± SD

47.1 ± 42.3

48.6 ± 45.4

43.3 ± 33.6

Molecular type [n (%)]

   

 HR+/HER2−

50 (71.4)

50 (100)

 

 Triple Neg

20 (28.6)

 

20 (100)

ER Positive [n (%)]

48 (68.6)

48 (96.0)

0

PR Positive [n (%)]

32 (45.7)

32 (64.0)

0

HER2 [n (%)]

   

 0

25 (35.7)

14 (28.0)

11 (55.0)

 1

24 (34.3)

19 (38.0)

5 (25.0)

 2

21 (30.0)

17 (34.0)

4 (20.0)

Ki67 high expression [n (%)]

   

 Yes

49 (70.0)

35 (70.0)

14 (70.0)

 No

19 (27.1)

13 (26.0)

6 (30.0)

 Missing

2 (2.9)

2 (4.0)

0

Metastasis

   

 Liver [n (%)]

37 (52.9)

29 (58.0)

8 (40.0)

 Lung [n (%)]

31 (44.3)

25 (50.0)

6 (30.0)

 Bone [n (%)]

48 (68.6)

39 (78.0)

9 (45.0)

 Brain [n (%)]

7 (10.0)

5 (10.0)

2 (10.0)

 Lymph node [n (%)]

34 (48.6)

20 (40.0)

14 (70.0)

CDK4/6i therapy [n (%)]

 

29 (58.0)

 

Stage at initial diagnosis [n (%)]

   

 I

1 (1.4)

1 (2.0)

0

 II

43 (61.4)

33 (66.0)

10 (50.0)

 III

14 (20.0)

9 (18.0)

5 (25.0)

 IV

9 (12.9)

5 (10.0)

4 (20.0)

 NA

2 (2.9)

1 (2.0)

1 (5.0)

 Missing

1 (1.4)

1 (2.0)

0

  1. BC breast cancer, BMI body mass index, CDK4/6i cyclin-dependent kinases 4 and 6 inhibitor, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HR hormone receptor, PR progesterone receptor, SD standard deviation, TNBC triple-negative breast cancer.
  2. aOne patient could not provide the duration of BC.
  3. 1. BMI = weight (kg)/height (m)*2;
  4. 2. Duration of disease (months) = (date of first study medication − date of diagnosis + 1)/30.4375;
  5. 3. Percentage (%) was calculated based on the total number of drug users as the denominator.
Back to article page